Torus Biosystems, a Cambridge MA-based company which specializes in infectious disease diagnostics, raised $25M in Series A funding.
The round was led by Northpond Ventures, with participation from prior investors including David Walt, PhD. In conjunction with the funding, Adam Wieschhaus, PhD, CFA, director at Northpond Ventures, will also join the Torus board.
The company intends to use the funds to accelerate commercialization of a syndromic testing solution designed for point-of-care use in ambulatory care settings.
Led by Shawn Marcell, CEO and co-founder, Torus Biosystems is an infectious disease diagnostics company currently developing syndromic testing solutions based on the integration of novel technologies, including qPCR and microarray technologies, that enable rapid, quantitative, and highly multiplexed detection of microbial pathogens, resistance genes and host immune-response markers that lead to improved patient outcomes.
The system is optimized for use in hospital outpatient and emergency departments, and convalescent settings.
Torus Biosystems is a spinout from the Harvard Wyss Institute for Biologically Inspired Engineering.